We are live on ! Find out more
KLDO

Kaleido Biosciences, Inc. Common Stock
KLDO

Delisted

KLDO was delisted on the 14th of April, 2022.

Back to rankings

3 hedge funds and large institutions have $31K invested in Kaleido Biosciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% less funds holding

Funds holding: 63 → 3 (-60)

100% less capital invested

Capital invested by funds: $55.1M → $31K (-$55.1M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 58

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-60
Holders Change %
-95.24%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
58
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
FP
Flagship Pioneering
Massachusetts
-$32.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$10.5M
3
HP
Harbourvest Partners
Massachusetts
-$3.03M
4
BlackRock
BlackRock
New York
-$1.51M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$1.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
1
Artal Group
Luxembourg
$31K – – –
FP
2
Flagship Pioneering
Massachusetts
– -$32.3M -19,575,710 Closed
Fidelity Investments
3
Fidelity Investments
Massachusetts
– -$10.5M -6,389,660 Closed
HP
4
Harbourvest Partners
Massachusetts
– -$3.03M -1,833,832 Closed
BlackRock
5
BlackRock
New York
– -$1.51M -913,506 Closed
Vanguard Group
6
Vanguard Group
Pennsylvania
– -$1.44M -870,602 Closed
Baillie Gifford & Co
7
Baillie Gifford & Co
United Kingdom
– -$1.21M -733,525 Closed
Federated Hermes
8
Federated Hermes
Pennsylvania
– -$1M -607,687 Closed
State Street
9
State Street
Massachusetts
– -$718K -435,024 Closed
Geode Capital Management
10
Geode Capital Management
Massachusetts
– -$555K -336,879 Closed
PAI
11
Palo Alto Investors
California
– -$511K -309,692 Closed
Northern Trust
12
Northern Trust
Illinois
– -$336K -203,833 Closed
Renaissance Technologies
13
Renaissance Technologies
New York
– -$143K -86,887 Closed
Millennium Management
14
Millennium Management
New York
– -$127K -77,006 Closed
Bank of New York Mellon
15
Bank of New York Mellon
New York
– -$99K -59,791 Closed
N
16
Nuveen
North Carolina
– -$97K -58,887 Closed
Charles Schwab
17
Charles Schwab
California
– -$68K -41,084 Closed
State Board of Administration of Florida Retirement System
18
State Board of Administration of Florida Retirement System
Florida
– -$56K -34,018 Closed
State of Wisconsin Investment Board
19
State of Wisconsin Investment Board
Wisconsin
– -$36K -21,900 Closed
IWM
20
IHT Wealth Management
Illinois
– -$31K -18,890 Closed
RhumbLine Advisers
21
RhumbLine Advisers
Massachusetts
– -$29K -17,394 Closed
Bank of America
22
Bank of America
North Carolina
– -$27K -16,228 Closed
Cerity Partners
23
Cerity Partners
New York
– -$26K -15,950 Closed
AllianceBernstein
24
AllianceBernstein
Tennessee
– -$23K -13,700 Closed
Citadel Advisors
25
Citadel Advisors
Florida
– -$21K -12,667 Closed
1
2 3

KLDO Hedge Fund Activity: Q2 2022 in Review

3 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q2 2022, worth a combined $31K — down 100% from $55.1M a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of KLDO and 0 opened new positions — a net loss of 58 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Flagship Pioneering, exiting entirely with an estimated $32.3M sold.

  • 3 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q2 2022, down from 63 in Q1 2022.
  • Funds reported $31K of Kaleido Biosciences, Inc. Common Stock stock for Q2 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q2 2022 and 58 closed out, a net change of -58 holders.
  • The largest Kaleido Biosciences, Inc. Common Stock seller in Q2 2022 was Flagship Pioneering, an estimated $32.3M sold.

Based on aggregated 13F filings for Q2 2022.